{
    "clinical_study": {
        "@rank": "52010", 
        "acronym": "AGRAH003", 
        "arm_group": {
            "arm_group_label": "Romiplostim", 
            "arm_group_type": "Experimental", 
            "description": "Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1\u00b5g/Kg to a maximum dose of 10 \u00b5g/Kg with a dose reduction schema in case of platelet overshoot"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I/II multicenter study which aims to assess the toxicity profile of\n      Romiplostim in patients with transfusion-dependent thrombocytopenia after allogeneic HSCT.\n\n      A total of 24 patients with transfusion-dependent thrombocytopenia after allogeneic HSCT\n      will be included.\n\n      The main endpoint is the incidence and severity of adverse events."
        }, 
        "brief_title": "Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must be \u2265 18 years, willing and able to sign informed consent\n\n          -  Patients could have been transplanted for hematological disorder (malignant or\n             non-malignant) excepted myelodysplastic syndromes patients and had received either a\n             myeloablative or a reduced intensity conditioning. All sources of allogeneic stem\n             cells are allowed.\n\n          -  Prolonged (> 2 months) transfusion-dependent thrombocytopenia\n\n          -  Screenings mean platelet count\u2264 20 x giga/L   or screenings mean platelet count \u2264 50\n             x giga/L   with a history of bleeding.\n\n          -  (ECOG) performance status of 0-2\n\n          -  Adequate liver function\n\n          -  Serum creatinine \u2264 176.8 \u03bcmol/L\n\n          -  Bone marrow aspirate with cytogenetics within 6 days of the first dose of romiplostim\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Relapse/progression of hematological malignancy (marrow examination required)\n\n          -  Non-controlled acute and/or chronic graft versus host disease (GvHD)\n\n          -  Active or uncontrolled infections\n\n          -  Cardiac pathology - Thrombosis\n\n          -  Pregnancy or breast feeding\n\n          -  Received interleukin-11 (IL-11) within 4 weeks of screening or previously received\n             any thrombopoietic growth factor\n\n          -  Patients on anticoagulant therapy\n\n          -  Receipt or planned receipt of Pegylated Granulocyte Colony Stimulating Factor\n             (PEG-G-CSF), or Granulocyte macrophage-colony stimulating factor (GM-CSF) within 4\n             weeks of the first dose of investigational product\n\n          -  Subject not using adequate contraceptive precautions, in the judgment of the\n             investigator\n\n          -  Sensitivity to any Escherichia coli-derived product\n\n          -  Inability to comply with study procedures.\n\n          -  Subject currently is enrolled in or has not yet completed 30 days since ending other\n             investigational device or drug study\n\n          -  No medical insurance in the French Health system"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980030", 
            "org_study_id": "P110204"
        }, 
        "intervention": {
            "arm_group_label": "Romiplostim", 
            "intervention_name": "Romiplostim", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "email": "gerard.socie@sls.aphp.fr", 
                "last_name": "G\u00e9rard Soci\u00e9, MD PhD", 
                "phone": "+33 1 42 49 98 24"
            }, 
            "contact_backup": {
                "email": "regis.peffaultdelatour@sls.aphp.fr", 
                "last_name": "R\u00e9gis PEFFAULT DE LA TOUR, MD PhD", 
                "phone": "+33 1 42 49 98 24"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "state": "Ile de France", 
                    "zip": "75010"
                }, 
                "name": "Saint Louis hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell", 
        "overall_contact": {
            "email": "gerard.socie@sls.aphp.fr", 
            "last_name": "G\u00e9rard Soci\u00e9, MD PhD", 
            "phone": "33 1 4249 98 24"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence and severity of all adverse events", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980030"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Dose of Romiplostim required to reach a platelet count above 50 x 109/L   in absence of platelet transfusion", 
                "measure": "Dose of Romiplostim", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "platelet count above 50 x 109/L   on 8 consecutive weeks independent of platelet transfusions", 
                "measure": "Durable platelet response after transplant:", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Relapse rate", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Graft versus host disease (GVHD)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Non relapse mortality rate", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "number of platelet transfusions", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Overall number of bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Incidence and duration of platelet hematological improvements above 20 x 109/L  and above 50 x 109/L  , respectively", 
                "measure": "platelet hematological improvements", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}